Representative immunotherapeutic modalities, especially checkpoint proteins such as programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) have achieved great success in some type of cancers in clinical settings (11). The gene discussed is PDCD1; the disease is cancer.